MedTrace Logo

Intravitreal Bevacizumab in Agioid Streaks

NCT00406250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-02-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of intravitreal bevacizumab in patients with choroidal neovascularization associated with angioid streaks.

Conditions

  • Angioid Streaks
  • Choroidal Neovascularization

Interventions

DRUG

intravitreal injection

1.25 mg in 0.05 cc of bevacizumab

DRUG

intravitreal injection

1.25 mg of bevacizumab intravitreally injected in a steril field

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    lead OTHER

Principal Investigators

  • Michele Rinaldi, MD · University of Campania Luigi Vanvitelli

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
44 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-12-31
Completion
2009-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406250 on ClinicalTrials.gov